MedTrace Logo

Doxil, Bevacizumab and Temsirolimus Trial

NCT00761644 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-04-11

No results posted yet for this study

Summary

The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer that has spread or is unable to be surgically removed. The safety and effectiveness of this combination of drugs will also be studied.

Conditions

Interventions

DRUG

Doxil

Day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.

DRUG

Bevacizumab

Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.

DRUG

Temsirolimus

Days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Daniel Karp, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-21
Primary Completion
2019-03-28
Completion
2019-03-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761644 on ClinicalTrials.gov